Lilly announces the formation of neuroscience and immunology business units.
Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology. Anne White, currently senior vice president and president of Lilly Oncology, will lead Lilly Neuroscience as senior vice president and president. An experienced leader in drug development who has led and grown Lilly's oncology business over the past several years, White will be responsible for Lilly's launched products and Phase III portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer's disease. The company recently announced Breakthrough Therapy designation for donanemab and its intention to submit a biologics license application (BLA) under the accelerated approval pathway later this year.
Patrik Jonsson will lead Lilly's launched products and Phase III portfolio of medicines in dermatology, gastroenterology and rheumatology as president, Lilly Immunology, in addition to his ongoing responsibilities as senior vice president and president, Lilly USA and chief customer officer. Lilly recently announced positive Phase III results for new biologic entities of mirikizumab for ulcerative colitis and lebrikizumab for atopic dermatitis.
.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins